APT Medical

APT Medical Financial Leverage

The Financial Leverage (Equity Multiplier) of APT Medical (688617.SS) as of Oct 22, 2026 is 1.18. In the previous year, Financial Leverage (Equity Multiplier) was 1.18 — a change of -0.09% (lower).

Financial Leverage

1.18

YoY

-0.09%

Last updated:

Financial Leverage (Equity Multiplier) of APT Medical is 2025 1.18 . Financial Leverage (Equity Multiplier) of APT Medical was 2024 1.18 . It decreases by -0.09% lower compared to the previous year.

The APT Medical Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.21 CNY
Jan 1, 2019
1.60 CNY
Jan 1, 2020
1.28 CNY
Jan 1, 2021
1.13 CNY
Jan 1, 2022
1.26 CNY
Jan 1, 2023
1.35 CNY
Jan 1, 2024
1.18 CNY
Jan 1, 2025
1.18 CNY
The APT Medical Financial Leverage history
YEARFinancial LeverageYoY
1.18-0.09%
1.18-12.20%
1.35+6.87%
1.26+11.50%
1.13-11.47%
1.28-20.31%
1.60+32.91%
1.21+2.32%
1.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

APT Medical Stock analysis

What does APT Medical do? APT Medical Inc generates revenue through the research, development, production, and sale of electrophysiology, coronary access, and peripheral vascular intervention medical devices. The company offers electrophysiological electrode catheters, controllable radiofrequency ablation electrode catheters, and multichannel electrophysiological systems under its electrophysiology product line. Its coronary access segment includes guide wires, micro catheters, balloons, contrast guide wires, and catheters. Peripheral vascular intervention products address peripheral vascular diseases and are sold domestically and internationally. The firm also engages in original equipment manufacturer (OEM) business, producing products for other brands. Domestic and overseas markets are the primary sales channels for all product segments. The company's electrophysiology products target healthcare providers specializing in cardiac procedures, while coronary access devices serve interventional cardiologists and vascular surgeons. Peripheral vascular intervention solutions are marketed to hospitals and clinics treating vascular conditions. OEM partnerships allow APT Medical to supply components to other medical device manufacturers without direct branding. These segments collectively drive revenue through direct sales to healthcare institutions and international distributors. APT Medical Inc's product portfolio includes electrophysiological systems and coronary access tools that cater to specific medical specialties. The firm's peripheral vascular intervention products are designed for treating conditions like peripheral artery disease. OEM business contributes to revenue by manufacturing components for other companies' branded products. Domestic market sales and overseas distribution networks form the core of the company's commercial strategy, with no mention of specific customer names or financial figures beyond the employee count. APT Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about APT Medical stock

Financial Leverage (Equity Multiplier) of APT Medical is 1.18 in 2025.

Financial Leverage (Equity Multiplier) of APT Medical changed from 1.18 to 1.18, representing a -0.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) APT Medical since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s APT Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — APT Medical

All Key Metrics — APT Medical